BioSpace News Archive

First patient dosed in trial investigating cardioversion of recent-onset atrial fibrillation [02-November-2021] SAN DIEGO , Nov. 2, 2021 /PRNewswire/ -- HUYABIO International (HUYABIO), the leader in accelerating global development of China’s pharmaceutical innovations, today announced that the first patient has been dosed in a Phase 2 study of HUYABIO’s novel drug

OncoResponse today announced initiation of a Phase 1/2 study of OR2805 in patients with advanced cancer. OR2805 is a fully human monoclonal antibody identified from an elite cancer responder

IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its third quarter 2021 financial and operating results on Tuesday, November 9, 2021.

OSSIO, Inc., an orthopedic fixation technology company, today announced the appointment of Gregory C. Berlet, MD, as its Chief Medical Officer.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the release of its inaugural Corporate Responsibility Report with primarily 2020 data and select 2021 highlights.

CytRx Corporation today commented on Orphazyme A/S’s (NASDAQ: ORPH) (“Orphazyme”) encouraging regulatory update following its recently held Type A meeting with the U.S. Food and Drug Administration (“FDA”) on arimoclomol

Amylyx Pharmaceuticals, Inc. today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for AMX0035 (sodium phenylbutyrate (PB) and taurursodiol (TURSO; also known as ursodoxicoltaurine)) for the treatment of amyotrophic lateral sclerosis (ALS).

Vivek Walimbe, Ph.D., former VP for Baxter Healthcare, to lead development of intracoronary imaging product and expand portfolio. Farzad Parsaie, with three decades of med device leadership, to oversee Quality and Regulatory Affairs.

Veracyte Announces New Data To Be Presented at SITC 2021 Will Highlight Company’s Immuno-Oncology Capabilities

Atreca, Inc., a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, announced financial results for the third quarter ended September 30, 2021, and provided an overview of recent developments.